Cornerstone pharmaceutical: avapritinib, a new anti-tumor drug, has been approved by FDA

January 15, 2020 / ayvakit, announced by American news agency / -- blueprint medicines, partner of cornerstone Pharmaceutical (Suzhou) Co., Ltd (hereinafter referred to as "cornerstone pharmaceutical", Hong Kong stock exchange code: 2616) Gamma Avapritinib has been approved by the U.S FDA on January 9, 2020 for the treatment of adult patients with inoperable or metastatic gastrointestinal stromal tumor (GIST) carrying mutations in exon 18 of PDGFRA (including mutations in pdgfrad842v) AYVAKIT Gamma Developed by blueprint medicine Dr Jiang Ningjun, chairman and chief executive officer of cornerstone pharmaceutical, said: "it's a great pleasure to see our cooperation product avapritinib with blueprint medicines in China approved in the United States, which is also the second FDA approved product in the product pipeline of cornerstone pharmaceutical The company plans to submit a new drug listing application to the National Drug Administration (nmpa) for the same indication in 2020 to meet the treatment needs of GIST patients with specific genetic characteristics in China " Cornerstone pharmaceutical has entered into exclusive cooperation and authorization with blueprint medicines, and obtained exclusive development and commercialization authorization for a number of drugs including avapritinib in Greater China Blueprint medicines reserves the right to develop and commercialize drugs in other parts of the world At present, avapritinib has two registration trials for gist in China Voyager, a phase III clinical study for third-line gist, has completed the enrollment of Chinese patients within four months Cornerstone pharmaceutical industry will also submit a new drug listing application for this indication to nmpa in the second half of 2020 About cornerstone Pharmaceutical (HKEx: 2616), a biopharmaceutical company, focuses on the development and commercialization of innovative tumor immunotherapy and precision treatment drugs to meet the keen medical needs of cancer patients in China and around the world Founded at the end of 2015, cornerstone pharmaceutical has assembled a world-class management team with rich experience in new drug research and development, clinical research and commercialization With tumor immunotherapy as the core, the company has established a rich product pipeline composed of 15 tumor candidate drugs At present, five late candidate drugs are in critical clinical trials With experienced management team, rich pipeline, business model focusing on clinical development and abundant funds, the vision of cornerstone pharmaceutical industry is to become a world-renowned leading biopharmaceutical company in China by bringing innovative cancer therapy to cancer patients around the world 37